22,000 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by Mcdonald Partners LLC

Mcdonald Partners LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,000 shares of the company’s stock, valued at approximately $358,000.

Other hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp acquired a new position in Elanco Animal Health during the fourth quarter worth $37,000. Tower Research Capital LLC TRC raised its stake in Elanco Animal Health by 169.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock valued at $93,000 after buying an additional 3,906 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Elanco Animal Health in the third quarter valued at $95,000. HBK Sorce Advisory LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at $169,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Elanco Animal Health by 10.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after buying an additional 1,127 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, Director William F. Doyle bought 15,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were bought at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the transaction, the director now owns 76,330 shares of the company’s stock, valued at approximately $1,296,083.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Stock Down 1.7 %

ELAN stock traded down $0.30 during trading on Tuesday, hitting $17.85. The company had a trading volume of 5,048,597 shares, compared to its average volume of 4,405,104. Elanco Animal Health Incorporated has a 1-year low of $8.52 and a 1-year high of $18.80. The firm has a 50-day moving average price of $16.21 and a 200-day moving average price of $15.62. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the previous year, the firm posted $0.45 EPS. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. Equities analysts predict that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Morgan Stanley raised their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler restated a “neutral” rating and issued a $19.00 price target (up from $18.00) on shares of Elanco Animal Health in a research note on Monday, May 13th. The Goldman Sachs Group raised their price target on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research note on Tuesday, February 27th. Finally, Barclays raised their price target on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.